1 week Ago By ABMN Staff
Shares of Legend Biotech Co. ( NASDAQ:LEGN – Get Free Report ) were down 3% on Friday . The company traded as low as $52.
44 and last traded at $52.45. Approximately 22,786 shares were traded during trading, a decline of 98% from the average daily volume of 1,020,766 shares.
The stock had previously closed at $54.05. Analysts Set New Price Targets A number of research analysts have weighed in on LEGN shares.
Truist Financial started coverage on shares of Legend Biotech in a research report on Monday, June 17th. They set a “buy” rating and a $88.00 price target on the stock.
Deutsche Bank Aktiengesellschaft started coverage on shares of Legend Biotech in a research report on Thursday, May 23rd. They set a “buy” rating and a $60.00 price target on the stock.
HC Wainwright reaffirmed a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a research report on Wednesday, August 28th. Scotiabank lifted their price target on shares of Legend Biotech from $70.
00 to $76.00 and gave the company a “sector outperform” rating in a research report on Monday, August 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $90.
00 price objective on shares of Legend Biotech in a research note on Monday, June 17th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Legend Biotech presently has an average rating of “Buy” and a consensus price target of $81.
78. Read Our Latest Stock Report on Legend Biotech Legend Biotech Trading Down 10.7 % Legend Biotech ( NASDAQ:LEGN – Get Free Report ) last announced its quarterly earnings results on Friday, August 9th.
The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.
49. Legend Biotech had a negative net margin of 62.50% and a negative return on equity of 23.
20%. The company had revenue of $186.50 million during the quarter, compared to the consensus estimate of $125.
25 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share.
The company’s revenue for the quarter was up 154.4% compared to the same quarter last year. As a group, equities research analysts predict that Legend Biotech Co.
will post -1.56 earnings per share for the current fiscal year. Hedge Funds Weigh In On Legend Biotech Several hedge funds and other institutional investors have recently modified their holdings of the company.
Swiss National Bank lifted its holdings in Legend Biotech by 10.3% in the fourth quarter. Swiss National Bank now owns 153,994 shares of the company’s stock worth $9,266,000 after purchasing an additional 14,400 shares during the period.
Teacher Retirement System of Texas lifted its holdings in Legend Biotech by 23.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,601 shares of the company’s stock worth $879,000 after purchasing an additional 2,752 shares during the period.
Boston Partners acquired a new stake in Legend Biotech in the fourth quarter worth about $613,000. Massachusetts Financial Services Co. MA lifted its holdings in Legend Biotech by 6.
3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,984,826 shares of the company’s stock worth $119,427,000 after purchasing an additional 117,794 shares during the period.
Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Legend Biotech by 19.
5% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd.
now owns 43,462 shares of the company’s stock worth $2,518,000 after purchasing an additional 7,093 shares during the period. Institutional investors and hedge funds own 70.89% of the company’s stock.
About Legend Biotech ( Get Free Report ) Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). Further Reading Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.
com's FREE daily email newsletter ..
